GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
|Poll|March 1, 2019
Mini Quiz: Health Professionals and Barriers to Psychiatric Treatment
Author(s)Adam Bartlett Hill, MD
In a national epidemic of caregiver distress and suicide, what barriers still stand in the way of seeking mental health treatment for medical professionals?
Advertisement
In a national epidemic of caregiver distress and suicide, what barriers still stand in the way of seeking mental health treatment for medical professionals?
Advertisement
Related to this article
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Ozempic Dilemma: Promises and Pitfalls in Psychiatry
2
Brain Trust: Bessel van der Kolk, MD, on Complex PTSD, Attachment, and the Limits of Pharmacotherapy
3
Why Generic Antidepressant Cycling Falls Short: Early Augmentation and TD Risk
4
Podcast: Campus Naloxone Access and Destigmatizing Substance Use Disorders
5